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1. Introduction  
Psoriasis is a common, chronic inflammatory and proliferative condition of the skin, 
sometimes affecting joints, in which both genetic and environmental influences play a 
critical role. Most characteristically, it consists of scaly, sharply demarcated red and 
indurated plaques, present particularly over extensor surfaces sometimes overlying the 
joints, and occasionally involving the scalp.  
2. Epidemiology 
Psoriasis affects between 2% and 3% of people worldwide. 1 This varies from an incidence of 
1.5% to 4.8% in Northern Europe 2  to China, where the lower prevalence of 0.3% has been 
observed. 3   Nearly one quarter of these have moderate to severe psoriasis consistent with 
involvement of >3% of body surface area. Women (OR = 1.37, 95% CI: 1.14–1.64) are slightly 
more likely than men and African Americans less likely than Caucasians (OR = 0.54; 95% CI: 
0.34–0.85) to report a psoriasis diagnosis. 4   
Psoriasis can develop at any age, but symptoms typically first appear between ages 15 and 
25 years. Approximately one half of patients diagnosed with psoriasis report suffering with 
pruritus. 5 In a large US survey, the average age of onset was 28 years, while in China it was 
36. In other studies, both sexes appear to be equally affected. Table 1 shows world-wide 
studies on prevalence of psoriasis.  
Looking at the white population in Rochester, MN, Bell et al reported an incidence of 60.4 
per 100,000 adjusted for sex and age, during the 1980 Rochester Epidemiology Project. 6 
From the same project Shbeeb et al looked at the population from 1982 and 1991 and 
reported a rising incidence to 107.7 per 100,000. 7 Those same increasing trends were 
confirmed by similar studies by Icen et al in the same population, and by Huerta et al 
looking at the population in the United Kingdom. 8  9 The reasons for this increase cannot be 
explained alone on known genetic factors. Other environmental influences or unknown 
genetic factors may play a role in this observation. The lack of obvious family history in 
many cases of newly diagnosed disease underscores this concept. 
3. Genetic & environmental causes 
3.1 Genetic basis of psoriasis 
A search for the genetic basis of psoriasis has been seriously undertaken by Gunnar Lomholt 
who studied heredity in residents of the Faroe Islands. Farber and Nall subsequently 
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studied the concordance rates in monozygotic twins and documented kindreds having 
multiple family members afflicted with the diseases. 10  11  Population studies revealed a 
higher incidence of psoriasis among first- and second-degree relatives than in the general 
population. However, just as the pathogenesis is complex, the mode of inheritance is also 
complex. Of nine distinct chromosomal loci, 7 of which have been clearly identified as being 
associated with psoriasis.  
 
World Region & Reference Prevalence (%) 
Europe  
Norway 1.4-4.8
Sweden 2.3
Denmark   28 2;5-3.2
United Kingdom   28 1.5-2.8
Croatia   28 1.55
Italy 0.8-4.5
Germany 2.5-3.5
France 3.58-5.2
Spain 1.43
Czechoslovakia   28 1.2
Hungary   28 2.0
Netherlands   28 1.8
New World  
North America  28 0.5 – 4.7
African-Americans 1.3
Newfoundland, Canada 2-3
South America  28  28 0.2-4.2
Caribbean 28  28 1.3-6.0
Africa  
West Africa  28 0.05-0.9
East Africa  28 2.8-3.5
North Africa  28 3.0
South Africa  28 1.5
Oceania  
Australian Aborigines 0.47
Australian Caucasians 2.3-2.57
Samoa Islands  28 0
Asia  
China  28  28 0.05-1.23 
Japan  28 0.29-1.18 
India  28 0.5-2.3
Malaysia  28 1.1-5.5
Table 1. Worldwide Prevalence of Psoriasis 
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The most important genetic determinant of psoriasis is PSORS1 (psoriasis susceptibility 
locus), widely considered to be a susceptibility locus for the development of psoriasis 
accounting probably for 35 to 50% of the heritability of the disease. 12 PSORS1 is found 
within the major histocompatibility complex (MHC) on chromosome 6p. Identification of 
the specific gene has been difficult because of the extensive linkage disequilibrium observed 
within the MHC. There are 3 genes within this locus that are strongly associated with 
inheriting the disease. 13 14 These genes code proteins that may be over-expressed in 
psoriasis.15 Others are found are exclusively found in the granular and cornified layers of 
the epidermis. 16 Studies show variants of psoriasis may be genetically heterogeneous. 
Guttate psoriasis appears to be strongly associated with PSORS1, 17 as opposed to late onset 
cases of psoriasis, generally occurring in persons over 50 years of age. 18  
 
Genetic Marker Chromosome Location Function Associated Diseases 
PSOR 1 
54, 55 19 
6p HLA-CW6 & 
corneodesmposin
?
PSOR 2 
62 
17q Immune synapse ?
IL12B 
63, 64 20 
5q T-cell 
differentiation
Crohn’s Disease 
IL23R 
55, 68, 69, 21  22 
 
1p T-cell 
differentiation 
Crohn’s Disease, 
ankylosing spondylitis, 
psoriatic arthritis, type 
I diabetes, celiac 
disease
ZNF 313 (RNF114) 
55 69 
20q Ubiquitin pathway ?
CDKAL1  23  24 
 
6p ? Crohn’s Disease, type 2 
diabetes mellitus 
PTPN22 
75,  25  26 
 
 
 
6p T cell signaling Type 1 diabetes 
mellitus, juvenile 
idiopathic arthritis, 
systemic lupus 
erythematosus, 
rheumatoid arthritis, 
autoimmune thyroid 
disease
IL-4 – IL-13 cytokine 
gene cluster 
55  27 
5q T-cell 
differentiation 
Crohn’s Disease 
(variant) 
LCE3B/3C 
66 28 
 
1q Epidermal 
differentiation 
 
Table 2. Genetic Markers associated with Psoriasis 
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PSORS2 is the second gene locus found associated with psoriasis. 29 Two genes in this 
region, SLC9A3R1 and NAT9, reside in chromosome 17q24-q25. 30 They contribute to the 
immunopathogenesis of psoriasis through their role on immunological synapse. This refers 
to the signaling accomplished by multimolecular complex formation between the mature T 
cell through its receptor (TCR), and the antigen presenting cell (APC). Through a series of 
adhesion molecules, like LFA-1, T cells can bind to ICAM-1 expressed in an adjacent cell like 
a keratinocyte or APC. The LFA-1 component was found particularly useful in therapy. By 
blocking this adhesion interaction, efalizumab was used to treat psoriasis. 31  Other adhesion 
molecules exist, and have been evaluated for a possible role in defining hereditary patterns 
of psoriasis and targeting these processes for therapy. For instance, LFA-3 Ig fusion protein 
(alefacept) has been found to reduce psoriasis lesions.32  
Additional findings suggest LCE3B/3C, located within the epidermal differentiation 
complex on chromosome 1, is also strongly associated with the development of psoriasis. 33  
Deletion of these genes is associated with a significant fraction in individuals of European 
ancestry with psoriasis. 34  Other genes that have been linked to psoriasis include ZNF313 
(allele RNF114), which plays a role in the ubiquitin pathway, and CDKAL1, the function of 
which is not known at this time. 35  PTPN22 plays a role in T cell signaling. Other 
associations involve variants of the gene encoding the IL-23 receptor (IL-23R) and a region 
of the IL-12B (p40) gene as being closely linked to risk for psoriasis. IL-23R also appears in 
association with psoriatic arthritis and ankylosing spondylitis. CDKAL1 shows association 
with psoriasis and Crohn’s disease, and type 2 diabetes mellitus. 36  37  Nearly all of the 
genes listed are associated with the immune response strongly implicating an immunologic 
basis for the pathogenesis of psoriasis. 
3.2 Environmental causes of psoriasis 
As with many other diseases, there are interactions between genetic factors and the 
environment. Psoriatic lesions appearing at the site of injury are a well known phenomenon 
(Koebner or isomorphic response). This injury can be a physical, chemical, electrical, 
infective, sun-burn or other inflammatory insult. The reverse Koebner phenomenon has also 
been observed to occur and refers to clearing of psoriasis after an injury or illness. 38 
Streptococcal infection has been shown to precede the onset of guttate psoriasis, especially 
in those with a family history of plaque psoriasis, and drugs have been implicated as an 
initial cause or exacerbating bouts of psoriasis. 39 Among these are lithium salts, 
antimalarials, beta-adrenergic blocking agents, non-steroidal anti-inflammatory drugs, 
angiotensin converting enzyme inhibitors, and the sudden withdrawal of corticosteroids. 40  
Other factors that may play a role include pregnancy, 41 alcohol, smoking, 42 psychogenic 
stress factors 43 and concomitant HIV disease and acquired immune deficiency. 44      
4. Psycho-social considerations 
Many patients with psoriasis, particularly those with severe disease, are frustrated with the 
management of their disease and the ineffectiveness of their therapies. A National Psoriasis 
Foundation (NPF) survey looking at a large number of patients revealed individuals 
suffering with psoriasis want to communicate their frustrations about their disease, and the 
disappointment about their treatments.45 
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Other studies reported that psoriasis sufferers experience difficulties in the workplace and 
in socialization with family members and friends, exclusion from public facilities, difficulties 
obtaining a job, and even contemplation of suicide. Other opinions expressed included 
feeling embarrassed, unattractive and depressed. The disease process was often described as 
a large problem in everyday life, influencing the choice of clothing used to cover psoriasis. 
Many claimed psoriasis interfered with their ability to sleep, and interfered with their sexual 
activities. About one third of those evaluated claimed having problems using their hands, 
walking, sitting, or standing for prolonged periods. 46 Another study reported 48% of 
respondents were not working, 20% of whom attributed their unemployment to their 
psoriasis or psoriatic arthritis. 47  
5. Clinical presentation – Subtypes of psoriasis (adults & children) 
Psoriasis most commonly presents as the chronic stable large plaque disorder commonly 
referred to as psoriasis vulgaris. The scales are silvery and have been described as 
“micaceous” on an underlying salmon pink in color. The thickened epidermis allows the 
cutaneous vessels to come very close to the scaly stratum corneum. Dislodging the scale in 
essence causes a tear in the epidermis resulting in bleeding, known as the Auspitz sign. 
Psoriasis plaques are characterized by thickened silvery white scales on a red base of skin. 
Lesions may occur as a few small plaques or become more widespread throughout the 
body. 48  In one survey, the most frequent symptoms experienced were scaling, itching, skin 
redness, lightness of the skin, bleeding at lesion sites, burning sensation, and fatigue. 49 
   
       a)                  b) 
Fig. 1. a) Large Chronic Plaque Psoriasis in an obese Caucasian and in a member of the 
Choclo natives of Southern Panama, with extensive plaques in spite of an outdoor life style 
while wearing minimal clothing. b) Guttate Psoriasis 
A ring of hypopigmented normal skin often surrounds the psoriatic plaque, commonly 
referred o as the Woronoff ring. 50  Customarily it appears as the skin tries to repair itself, an 
has been used as an indication therapy is working. 51  52  
Guttate psoriasis describes a “shower” of smaller less scaly and erythematous lesions 
appearing in a widespread to generalized distribution. They occur less commonly on the 
face. This variant occurs more commonly in children and young adults, often secondary to 
an acute infection, usually streptococcal.  
Erythrodermic psoriasis results when chronic lesions evolve and coalesce into a generalized 
exfoliative phase. In this scenario it behaves either like an extensive form of large plaque 
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psoriasis, which generally responds to therapy, or as the “unstable” form of psoriasis which 
can result from discontinuation of systemic corticosteroids, 53 Not commonly it can seen 
with joint involvement, or as the end result of a generalized pustular psoriasis. Individuals 
with this form tend to be febrile, highly resistant to tolerating any topical regimen, or 
phototherapy, and can present with metabolic complications related to sweating imbalance 
leading to abnormal thermoregulation, electrolyte abnormalities, intestinal absorption, and 
negative protein balance. 54 55  56  
 
Histological changes of psoriasis (hematoxylin and eosin), from a punch biopsy of a large plque, shows 
epidermal thickening with parakeratosis, and elongation of the rete ridges with mixed cellular infiltrate 
– T-cells an polymorphonuclear neutrophils (PMN). Vascular dilatation, and microabscesses (Munroe) 
with PMN form with disease progression. 
  
 
 
Fig. 2. Histologic Features of Psoriasis 
Another manner to categorize psoriasis involves the anatomical distribution. Scalp psoriasis 
can be a part of large plaque psoriasis. Often it is seen as the sole anatomic area involved in the 
skin, presenting a therapeutic challenge due to the very thick nature of the plaques that form. 
Genital involvement in males and females may occur as part of widespread disease or as a 
sole manifestation involving the glans mimicking erythroplasia or Zoon’s balanitis. 
Sometimes, it can also occur on the flexural surface of the groins and vulva as part of inverse 
psoriasis, which can also exist on the axillas, submammary, gluteal cleft and other body 
folds. This is more common in older adults. Scaling is greatly reduced. Failure of these 
eruptions to respond to suspected fungal or yeast infections should raise suspicion.  
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Hands and feet may occur as well-defined plaques resembling hyperkeratotic eczema 
(palmo-plantar plaque psoriasis), or as a pustulosis, (palmo-plantar pustular psoriasis) or as 
a mixture of the two. It can be seen in connection with occupational use of irritants. 57 
 
Fig. 3. Erythrodermic psoriasis & psoriatic arthritis with chronic joint deformity  
    
   
Fig. 4. Palmoplantar Plaque Psoriasis 
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Nail involvement can be seen in association with all types of psoriasis. It can be a predictor 
of psoriatic arthropathy, and as such is often seen in psoriatic patients with psoriatic 
arthritis. 58 Although pitting is the most frequent change seen, discoloration, subungual 
hyperkeratosis, and onycholysis are common. Splinter hemorrhages can occur. Nail disease 
is more severe in familial cases and when disease onset is early. Patients over 40 years of age 
are twice as affected as those under 20. 59 Longitudinal biopsy of the nail bed and matrix 
studies have shed some light on the cause of these changes. 60 Nail pits, ridges and grooves 
result from psoriasis of the nail matrix, whereas onycholysis, subungual hyperkeratosis, and 
splinter hemorrhages are attributable to disease of the nail bed or hyponychium. 61  Circular 
discoloration of the nail bed and hyponychium may resemble an “oil drop” below the nail. 
This observation represents histologically psoriatic change in the hyponychium. 62 Candidal 
onychomycosis is a common find in psoriatic nails, but dermatophytes are rare. 63 
   
Fig. 5. Nail changes in Psoriasis 
5.1 Psoriasis in children 
Psoriasis occurs approximately 1/3 of the time during the first two decades of life, and is 
therefore quite common in children. 64 Guttate psoriasis is frequently seen in children. 
Inverse psoriasis can present in the form of a toe cleft intertrigo, a chronic blepharitis, or 
perleche on the angle of the mouth or a lateral eye lid. Psoriasis on the face occurs more 
often in children than in adults. Scalp involvement and a psoriatic rash in the napkin area 
are common.  
5.2 Differential diagnosis  
The rash of eczema, at times, can present with a psoriasiform appearance. As mentioned 
previously, psoriasis of the hands can appear indistinguishable from contact dermatitis, 
since irritants can often exacerbate or herald onset of activity. Lichen planus (LP) can at 
times have a dusky red presentation similar to early psoriasis. LP can also coexist with 
psoriasis. When involving skin close to the elbows, knees or shins, lichen simplex can mimic 
psoriasis. Pityriasis lichenoides chronica or Muccha-Habermann Disease, can appear like 
guttate psoriasis. Skin biopsy is sometimes necessary to differentiate these entities. 
Candidiasis, particularly in the flexural areas has been mistaken for psoriasis. 
Dermatophytosis is generally differentiated from psoriasis by the nature of the scale that 
spreads over the expanding margins. Pityriasis rubra pilaris and secondary syphilis can be 
confused with erythroderma. Lymphoma of the skin, and toxic erythema caused by drugs 
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can present similarly with an erythrodermic presentation. Psoriasis cutaneous lymphoma, 
and leprosy are three clinical entities that can typically present with secondary lesions that 
have “skip areas.” This refers to islands of normal skin appearing within the lesion.  
5.3 Psoriatic arthritis 
Psoriatic arthritis (PsA) is inflammatory in nature. These patients tend to present with pain, 
stiffness, and swelling of affected joints. 65 Up to 30% of psoriatic patients have PsA, a 
progressive and destructive disease. Psoriatic arthritis usually develops between 30-50 years of 
age. Generally, skin symptoms appear earlier than joint symptoms (70% of cases). Likelihood 
of developing PsA may also correlate with duration and severity of psoriasis. However, in 15 
% of patients, the joint manifestations may appear before the skin changes by as many as 10-15 
years. In the remaining 15% the skin and joint symptoms appear simultaneously. Sensitizing 
clinicians to the morbidity of these diseases may aid in optimizing psoriasis management and 
patient care. 66  67  68  69  70 Nail involvement is observed in 70-80% of these patients making this 
clinical observation a valuable predictive clinical sign for the development of PsA. 28  71  
Severity of nail disease correlates with severity of skin disease. As early as 2008, the American 
Academy of Dermatology (AAD) issued guidelines for the management of psoriasis and 
psoriatic arthritis. The most commonly affected joints were listed to be those in the wrist, 
knees, ankles, lower back, and neck. 72 
Prolonged morning stiffness, lasting longer than 60 minutes, is a common complaint, and 
results from inflammatory involvement of entheses, the point at which tendons or ligaments 
insert to bone. It tends to improve throughout the day. What begins as oligoarthritis (4 or 
less joints) may progress to polyarticular (more than 4 joints) over years, and may revert 
back to oligoarthritis with treatment. Though patterns of presentation are not helpful to 
identify PsA, the distal inter-phalangeal joint (DIP) may be the most readily recognizable 
because it is unique to PsA. It occurs in 5%-10% of patients and is seen predominantly in 
men. An asymmetric oligoarthritis occurs in 30% of cases, a large joint is generally involved 
like a knee, in association with a few small joints of the hands and feet, commonly with 
dactylitis. The polyarthritis pattern, practically as common, is seen more often in women, it 
involves fingers, wrists, toes and ankles. It involves DIP joints and is asymmetric. In 
comparison with RA, in PsA all joints of one digit tend to be involved while sparing other 
digits, whereas in RA the same joint is involved in all the digits. Whereas synovitis is the 
primary lesion of rheumatoid arthritis (RA), synovitis along with enthesitis characterizes 
PsA. 73 The most common sites of entheseal involvement in PsA include the attachment of 
the Achilles tendon or the plantar fascia to the calcaneus, as well as the ligaments around 
the rib cage, pelvis, vertebral bodies, posterior tibial tendon, quadriceps muscle, patellar 
tendon, and the elbow.  
Arthritis mutilans of hands and feet occurs infrequently, about 5% of the times. Axial disease, 
when it occurs alone, is equally infrequent and is seen in 5% of cases. More commonly, it is 
seen in association with peripheral arthritis. About 40% of patients in general have some form 
of axial disease. The cervical pine is involved more frequently than the thoraco-lumbar. 74  
Constitutional symptoms associated with PsA are similar to those observed in other types of 
inflammatory arthritis, and include fatigue, anorexia, weight loss and general weakness. 
Conjunctivitis and or uveitis (pain, lacrimation and photophobia) may present in up to 1/3 
of cases. It tends to be chronic and bilateral.  
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5.3.1 Physical examination  
Proper evaluation requires an examination of all joints; this includes the feet, which often 
reveal significant pathology. Erythema overlying the joints, and often over the distal 
phalanges is often seen in hands as well as feet. Selling of the second and third metacarpo-
phalangeal joint of the hands may be prominent. Swelling of the large joints like the knees 
may be noted as well. Dactylitis or fusiform swelling of the digits or toes is the result of 
inflammation of the phalangeal joints along with enthesitis. Mutilating psoriatic arthritis can 
result with shortening of the fingers opera (opera glass or telescoping effect). 
5.3.2 Laboratory & imaging studies 
There is no specific serologic marker for PsA. Though acute phase reactants like CRP, and 
ESR may be elevated, they are far from specific. HLAB27 is not much better in specificity. 
While it may appear in 50%-70% of sufferer with axial disease, and less than 15% of those 
with peripheral disease, it may appear in 7% of normal North American Caucasians, and its 
presence is independent of disease severity. 75  
Imaging findings center on visualizing radiographic evidence of new bone proliferation or 
periostitis observed adjacent to erosions, and at sites of entheseal attachments. Marginal 
erosions of bones may progress to involve the central articular surface resulting in the 
characteristic “pencil in cup” finding. This progressive loss of bone results in collapse of the 
phalanges and metacarpal bone resulting in the opera glass or telescoping deformity. MRI and 
ultrasound are of greater value than plain radiographic film when evaluating the presence of 
enthesitis. 76 Rheumatoid Factor (RF) may help confirm the diagnosis of RA (at least in 2/3 of 
the cases); however, RF is positive in 5% of adults, increasing in frequency with age, so that 20% 
of those over 65 years of age may have a positive RF. In patients with PsA, RF may be positive 
5%-10% of the time. Even antibodies to citrullinated-containing proteins (AntiCCP) with 
improved sensitivity and specificity over RF for RA, are positive in PsA in less than 7%. 77 
 
Fig. 6. Nuclear scan of hands and feet - in a psoriatic patient showing asymmetric uptake of 
radiolabeled Technitium-99 material taken up by inflamed joints 
5.3.3 Classification of psoriatic arthritis 
Two types of classification (Moll & Wright and CASPAR) are commonly used to categorize 
psoriatic arthritis. It is often helpful to use one of these when describing clinical severity. 
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This exercise is useful when seeking approval for systemic therapy from government or 
private insurance carriers. According to the AAD, the Moll and Wright criteria for 
classifying psoriatic arthritis, developed in 1973, are frequently used. The Moll & Wright 
Classification criteria have a specificity of 98% and a sensitivity of 91%.  
To meet the Moll and Wright classification criteria, a patient must present with psoriasis, 
and seronegative inflammatory arthritis with one of several different criteria including: 
 Polyarticular, symmetric arthritis (rheumatoid arthritis-like) 
 Oligoarticular (< 5 joints), asymmetric arthritis 
 Distal interphalangeal joint predominant 
 Spondylitis predominant 
 Arthritis mutilans 
The CASPAR (classification criteria for psoriatic arthritis) criteria consist of established 
inflammatory arthritis defined by the presence of tender and swollen joints and prolonged 
morning- or immobility-induced stiffness with at least 3 points from the following 
features1,2: 
 Current psoriasis (assigned a score of 2; all other features are assigned a score of 1) 
 A personal history of psoriasis (unless current psoriasis is present) 
 A family history of psoriasis (unless current psoriasis is present or there is a personal 
history of psoriasis) 
 Current dactylitis or history of dactylitis recorded by a rheumatologist 
 Juxtaarticular new bone formation 
 Rheumatoid factor negativity 
 Typical psoriasis nail dystrophy including onycholysis, pitting, and hyperkeratosis 
The CASPAR criteria have a specificity of 99% and a sensitivity of 91%. 28  28  
5.4 Psoriasis Area and Severity Index (PASI) & its role in clinical research 
Psoriasis Area and Severity Index (PASI) score provides a means of assessing psoriasis that 
takes into account both the severity and extent of disease. The PASI score for an 
individual patient is calculated by adding the scores of the four body regions: the head, 
the trunk, the arms, and the legs. It ranges from 0 to 72. 78 The score for a single region is 
obtained by multiplying the percentage of surface area occupied by the region (e.g., 0.1 
for the head) times the degree of involvement for that region, assessed on a scale of 0 to 6. 
The result is multiplied by the overall severity score for the region, defined as the sum of 
scores for redness, thickness, and scale, calculated on a scale of 0 to 4. The resultant scores 
are then added for each body region to yield the overall PASI score. The PASI has become 
a tool for measuring disease severity and evaluating how a therapeutic agent lowers the 
subject’s score.  
One problem with this index is that it presumes the area of involvement corresponds with 
severity of disease. It would be possible for a patient with thick plaques on the scalp, elbows 
and knees to have the same score as one having minimal plaques in the arms and trunk. The 
former would pose a therapeutic challenge in comparison with the latter, yet their index 
scores would fail to capture this discrepancy. 
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Fig. 7. PASI Score scale. In the example shown here, the score for the trunk is obtained by 
multiplying 0.3 x 2 x  the sum of 2 + 2 + 2, to yield a score of 3.6. When the scores for the 
four regions are added, we get a PASI Score of 17.1. 
Other indices used to categorize disease severity include body surface area (BSA), 
dermatology life quality index (DQLI), .79 and the global physician assessment (GPA). 80 
Puzenat et al studies a group of indices used to evaluate psoriasis severity. Based on this 
systematic review, it appears that none of the severity scores used for psoriasis meets all of 
the validation criteria required for an ideal score. However, we can conclude that the PASI 
score is the most extensively studied psoriasis clinical severity score and the most 
thoroughly validated according to methodological validation criteria. Despite certain 
limitations, use of the PASI score can be recommended for scientific evaluation of the 
clinical severity of psoriasis. 81 
6. Immunopathophysiology  
The cytokine networking theory for the cause of psoriasis was postulated 20 years ago. 82 
Proponents maintain that cytokines rather than non-protein type mediators like eicosanoids, 
orchestrate the multicellular conspiracy among immunocytes such as dentritic cells and T-
cells as well as the cross talk between immunocytes and epidermal keratinocytes that 
culminates in the formation of the psoriatic plaque. There is mounting evidence the innate 
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immune system, by carrying out its intended role of providing an early response mechanism 
against harm to the host through its nonspecific effectors, may also help induce psoriasis. 83 
Plasmacytoid dentritic cells, the foremost producers of interferon-ǂ, a documented inducer 
of psoriasis,84 are activated and increased in psoriatic lesions through complexes of the 
antimicrobial peptide LL37 (cathelicidin) and DNA in a toll-like receptor (TLR) 9 – dependent 
manner. 85 This provides a possible explanation of the mechanism by which host DNA is 
turned into a proinflammatory stimulus that breaks the immunologic tolerance in psoriasis. 
Psoriatic keratinocytes are a rich source of antimicrobial peptides, including IL37, ǃ- 
defensins, and S100A7 (psoriasin). These antimicrobial peptides also have strong chemotactic 
properties, and can help direct other cell functions in dendritic cells and T-cells. In addition, 
keratinocytes have a potential accessory role in skin immune response. They respond to 
cytokines derived from dendritic cells and T-cells including interferons, TNF, IL-17, & the 
IL-20 family of cytokines. They can also produce proinflammatory cytokines like IL-1, IL-6, 
TNF- ǂ, and chemokines like IL-8 (CXCL*), CXCL10, and CCL20. (see Figure 1)  
Dendritic cells bridge the gap between innate and adaptive immunity. Myeloid dermal 
dendritic cells are increased in psoriatic lesions and induce autoproliferation of T-cells and 
TH1 cells. 86  A specialized subgroup (TIP dendritic cells) produce TNF- ǂ, and inducible 
nitric oxide synthetase. 87 Targeted immunotherapy and psoralen  and ultraviolet A (PUVA) 
therapy reduce the  number of dendritic cells in psoriatic patients, adding validity to the role 
these cells play in the pathogenesis of psoriasis.88 Clearly, it becomes evident the psoriatic 
inflammatory response is shaped by a complex interface between elements of the innate and 
the adaptive immune response. 89 
In two different studies, Zheng et al 90 and Chan 91 give IL-23 a potential role in the 
pathogenesis of psoriasis. Injecting IL-12 into mice skin leads to increased IFN-Ǆ, whereas 
IL-23 injections increased production of other cytokines including IL-17 and IL-22, but not 
INF-Ǆ. The traditional belief has been to categorize IL-12 and IFN-Ǆ producing immunocytes 
as TH1 type, promoting a cell-mediated immune response to intracellular pathogens. In 
contrast, T cells producing another collection of cytokines such as IL-4, IL-5, and IL-13 
promote a humoral or antibody response to combat extracellular pathogens in a classical 
TH2 type reaction. A new cytokine network has been identified belonging to the CD4+ subset 
producing a different set of cytokines. This third effector cell is the TH17, and it is directed 
by IL-23 with help from transforming growth factor (TGF-ǃ) and IL-7 92  It is apparent that 
through the promotion of TH17 cells, IL-23 can play a role in the clearance of infections 
agents, but has the ability of mediating autoimmune inflammatory disease such as psoriasis 
and Crohn’s Disease. These TH17 cells produce IL-22, which is responsible for the epidermal 
thickening seen on psoriasis, and the production of antimicrobial peptides as well as 
chemokines (including Il-17, and Il-22). 28  It is believed this may be accomplished through 
the phosphorilation of Sta3, which has been found elevated in psoriatic plaques. 93 IL-22 also 
mediates the keratinocyte production of defensins & other molecules (antimicrobial 
cytokines) that help enhance the mobility and amplification of the inflammatory response 
leading to the phenotype of psoriasis 94 95 With successful anti-TNF treatment, TH17 cells are 
reduced, adding still further support to their functional role in psoriasis. 96  Figure 1 
illustrates how targeting specific focal points responsible for the pathogenesis of psoriasis 
may lead to effective prevention of disease and its progression. 
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Fig. 8. Key Cells  & Mediators in the transition from innate to adaptive immunity in the 
pathophysiology of psoriasis 
Innate immature cells produce key cytokines (TNF-ǂ, interferon- ǂ, interferon-Ǆ, interleukin-
1ǃ and interleukin 6) that activate myloid dendritic cells. Activated dendritic cells present 
antigens and secrete mediators such as interleukin-12 and interleukin-23, leading to the 
differentiation of type 17 and type 1 helper T cells (Th17 and Th1). T cells, in turn, secrete 
mediators (e.g. interleukin-17A, interleukin-17F, and interleukin-22) that activate keratinocytes 
and induce the production of antimicrobial peptides ( e.g.LL-37 cathelicidin and ǃ-defensins), 
proinflammatory cytokines (TNF-ǂ, interleukin-1ǃ, and interleukin 6), chemokines (CXCL8 
through CXCL11 and CCL20) and S100 proteins. These soluble mediators feed back into the 
proinflammatory disease cycle and shape the inflammatory infiltrate.  
It seems possessing the gene encoding the IL23 receptor (IL23R) confers strong protection 
against Crohn Disease  97  Chan et al showed other molecules cross talk between IL23 
activated monocytes and the epidermal response including TNF-ǂ and members of the IL19 
mainly (IL19, IL20, IL24). IL23 induced epidermal response was depended on the presence 
of TNF-ǂ as well as the IL20R receptor – which is shared by IL19 family members. There is 
observed reciprocal exchange of signals between epidermal keratinocytes and immunocytes.  
An effort has been ongoing to search for that elusive high-affinity foreign antigen possibly 
derived from an infectious agent to drive the distinct cell clones in the clonal adaptive 
immune response. However, to date, no clonal T-cell expansion has been consistently 
indentified. Alternatively, investigators began to look at the innate immune system as the 
www.intechopen.com
 Psoriasis 
 
173 
one responsible for contributing to an inappropriate local tissue inflammatory reaction in 
psoriasis. It has been noted that IL-23 has been implicated in local mucosal 
immunopathology by means of innate immune mechanisms. 98 Noting that dendritic cells 
serve as the bridge between the innate and the adaptive immune system, it may well be it is 
not an antigenic stimulus that sparks the process, but a genetically programmed 
hyperactivity of these cells through their altered mechanism of immunologic synapse. 
As a final thought in this section, vitamin D and its analogs have been well established as 
therapeutic agents in the treatment of psoriasis. The mechanism of action by which these 
agents improve psoriasis is via the vitamin D receptor (VDR), which mediates its effects on 
the proliferation and differentiation of epidermal keratinocytes,99 100 and on the 
immunological features of psoriasis, including shifting the TH 1 cytokine profile of plaques 
towards a TH 2 cytokine profile. 101  
    
Fig. 9. Overview of the immunopathophysiology of Psoriasis 
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Vitamin D, through its action by interaction with the VDR offers a beneficial effect on 
reducing the psoriatic plaque. Keratinocyte differentiation is evident through observed 
increased levels of transglutaminase I and involucrin and enhanced cornified envelope 
formation of suprabasal cells 102  103 , and down regulation of epidermal growth factor, 
keratin & other markers. The immunomodulatory activity of VDR includes a decrease in the 
expression or protein levels of IL-2, IL-6, IL-8, IFNǄ and GM-CSF. These cytokines play a 
role in cutaneous inflammation and proliferation of T-lymphocytes and keratinocytes. The 
expression of IL-12 and GMCSF is negatively regulated through VDR by ligand-dependent 
inhibition of NF-AT-AP1 composite element activity. 104  105 1ǂ,25-dihydroxyvitamin D3 and 
calcipotriol have also been shown to increase the expression of the receptor for the anti-
inflammatory cytokine IL-10 in cultured keratinocytes. 106  107 
The overall scheme illustrating the various players in the process that leads to the 
development of psoriasis is illustrated in Figure 2. 
7. Comorbidities & other medical considerations 
The basis for these observations began from noting psoriasis is characterized by increased T-
cell activation leading to production of various cytokines leading to inflammation in the 
skin as well as other organ targets. 28 These next sections will look at recent data exploring 
the possibility of a link between psoriasis and cardiovascular disease, chronic obstructive 
pulmonary disease, metabolic syndrome and obesity, diabetes, pregnancy, celiac disease, 
and malignancies.    
7.1 Cardiovascular disease 
Psoriasis may be a risk factor for development of coronary artery calcification (CAC) 
according to a small study in which 32 patients with psoriasis and 32 matched controls were 
compared to assess their degree of CAC using non-contrast-enhanced, 16-row, spiral 
computed tomography. Patients and controls were matched for age, sex, race, 
cardiovascular risk factors with the exception of family history of cardiovascular diseases. 
CAC scores were determined for these various individuals and the scores were correlated 
with the likelihood of coronary artery disease (CAD). Nearly 72% of control patients were 
found to be free of evidence of CAC, as opposed to only 40.6% of psoriasis patients. In the 
category where stenosis was likely to be found (those with a CAC score 101-400), 9.4% of 
control subjects were found to have CAD in comparison with 18.8% in the psoriasis group. 
For those subjects with a CAC score above 400, no patient in the control group was found to 
have CAD; whereas 6.3% of the psoriasis group showed nearly certain evidence of CAD. 108  
In one larger study investigators from the United Kingdom employed the General Practice 
Research Database (UKGPRD) to determine whether severe psoriasis is associated with an 
increases risk of cardiovascular mortality. They identified 3603 patients with severe 
psoriasis, and compared that to 14,330 who had no history of psoriasis. Severe psoriasis was 
defined as anyone given the diagnosis of severe psoriasis, and systemic therapy consistent 
with severe psoriasis. The unadjusted risk of mortality measures incidence per 1,000 person-
years, due to cardiovascular disease, and was significantly increased in patients with severe 
psoriasis (8.75), compared with unexposed patients (6.19). Even as severe psoriasis was 
shown to be an independent risk factor for death due to cardiovascular disease, after 
adjusting for traditional cardiovascular risk factors (age, sex, hyperlipidemia, hypertension, 
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smoking, diabetes), the relative risk (RR) of cardiovascular death associated with severe 
psoriasis was highest in younger individuals with a RR of cardiovascular death of 2.69 for a 
40-year-old, as opposed to 1.92 for a 60-year old. 109   
Using the UKGPRD, Gelfand et al embarked in a more ambitious prospective, population-
based cohort study. Patients with psoriasis (aged 20 to 90 years) were compared with a 
matched sample of persons without psoriasis from 1987 to 2002. There were 555,995 
controls, 127,139 patients with mild psoriasis, and 3837 patients with severe psoriasis 
(defined like in the previous study). The rates of myocardial infarction (MI) were compared 
between controls and psoriasis patients after a mean follow-up time of 4-5 years. Out of the 
group of patients with mild disease the adjusted relative risk for MI was 1.54, while the rate 
in the group having severe psoriatic disease was 7.08. Separating the groups according to 
age showed similar results as the earlier study. The younger individuals displayed a greater 
risk for MI than older patients, and severity of disease was again proportionally more likely 
to confer a greater risk in the younger age group. Additional analysis suggested men and 
women with severe psoriasis died 3.5 and 4.4 years younger respectively than patients 
without psoriasis. The results persisted after adjustment for risk factors associated with 
mortality. 110 Further evaluation of this data in a recent publication concluded severe 
psoriasis confers an additional 6.2% absolute risk of 10-year rate of major adverse cardiac 
events compared to the general population. This has important therapeutic implications for 
cardiovascular risk stratification and prevention in patients with severe psoriasis. 111 
Very similar results were obtained in a study of two US health care databases analyzed 
adult patients at least 17 years old in 2001. The population examined totaled around 17 
million. Cardiovascular disease (CVD) or CVD risk factors generally increased with disease 
severity. Severe disease was defined as disease requiring at least one systemic drug. In both 
databases, higher disease severity raised the risk for coronary heart failure, diabetes mellitus 
(type 2), hypertension, and ischemic heart disease. 112 An observational study analyzed 
computerized records of all outpatients who were diagnosed with psoriasis between 
January 1, 1985 and December 31, 2005 at the Miami VA Medical Center. A total of 3,236 
patients with psoriasis and 2,500 controls were evaluated. An association was observed 
between psoriasis and coronary artery, cerebrovascular, and peripheral vascular diseases.113  
Osteopontin is a phosphoprotein secreted by osteoblasts, lymphocytes, macrophages, 
epithelial cells, and smooth muscle cells. It is a byproduct of inflammation, and has been 
known to be elevated in patients with atherosclerotic heart disease. Chen et al have noted 
increased levels of osteopontin in patients with psoriasis, and have suggested it be a 
cardiovascular risk factor for patients suffering with psoriasis, further validating the notion 
inflammatory factors may coexist in both heart disease and psoriasis. 114   
Anti-TNF therapy may reduce risk for MI in patients with psoriasis. A retrospective cohort 
group study at Kaiser Permanente in Southern California looked at 30,467 patients from 
January 2004 to December 2008 The average age was 50.2 years, with 48.4% being males. 
Severe psoriasis was defined as anyone getting systemic therapy including phototherapy. 
There were 5,392 (18%) patients in this group. The TNF-ǂ inhibitor cohort had 2,064 (7%) 
patients. The overall MI rate was 0.42 per 100 patient years for all patients, while the cohort 
that had mild psoriasis had an MI rate of 0.43 per 100 patient year, and the severe psoriasis 
group had a rate of 0.44 per 100 patient years. Patients treated with a TNFǂ antagonist 
showed a rate of 0.34 per 100 patient years. This data suggest that effective therapy with a 
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TNF-ǂ antagonist should reverse the cardiovascular risk profile for patients that respond to 
this therapy. Further research is needed before this claim can be verified. 115 
7.2 Metabolic syndrome & obesity 
Metabolic syndrome is a cluster of risk factors that often accompany obesity, and is 
associated with increased risk for atherosclerotic cardiovascular disease and type 2 diabetes. 
The 5 components of metabolic syndrome, as defined by the United States National 
Cholesterol Education Program, are abdominal obesity (measured by waist circumference), 
elevated fasting glucose (suggestive of insulin resistance), hypertension, 
hypertriglyceridemia and, reduced high-density lipoprotein cholesterol (HDL-C). Persons 
meeting any 3 or more of these 5 criteria are now considered to have metabolic syndrome. 
The metabolic syndrome is a cluster of risk factors that often accompany obesity and are 
associated with increased risk for cardiovascular disease and type 2 diabetes. Certain 
adjustments to waist circumference measurement should be made for persons of Asian 
origin (cut point ≥ 90 cm in men and ≥ 80 cm in women). The prevalence of metabolic 
syndrome in the US is estimated to be 22.8% among men and 22.6% among women. It is 
highest among those of Mexican-American heritage and lowest in blacks. 116   117  118 
It has been suggested that there may be a relationship between the risk of psoriasis, and 
obesity. Both conditions result in a state of chronic systemic inflammation that can have 
deleterious effects on cardiovascular health, glucose, and lipid metabolism. Obesity is 
associated with a state of chronic low-level inflammation and the presence of inflammatory 
cytokines, particularly tumor necrosis factor alpha (TNF-ǂ), which are presumed to derive 
from macrophages into adipose tissue or activated adipocytes themselves. 119  120  121  122  123 
Adipocytes (fat cells) store lipids and regulate metabolic homeostasis under normal 
conditions, while macrophages play a key role in the inflammatory response. 
However, each has the ability to perform both functions if necessary. Both types of cells 
share certain common features, including production of inflammatory cytokines and fatty 
acid binding proteins. In obese persons, infiltration of macrophages into adipose tissue and 
release of inflammatory cytokines by adipocytes results in adipocytes becoming inflamed. 
Several of the cytokines released by adipocytes affect the immune stress response, and many 
more are key to inflammation (TNF-ǂ, interleukin-6).124 125  126        
In a recent survey conducted by the National Psoriasis Foundation, many psoriasis and 
psoriatic arthritis patients surveyed reported having at least one other critical health 
condition. Of those surveyed, almost 70% were overweight or obese; 28% had another 
chronic inflammatory disease such as lupus, Crohn’s disease, or multiple sclerosis; while 
24% of patients had hypercholesterolemia. Survey responses were obtained between 2004 
and 2009 from telephone and internet surveys. Survey respondents were screened so that 
75% had moderate to severe psoriasis, based on expected body surface area (BSA) coverage 
of 3% or greater without medication, while the remaining 25% had mild disease, or BSA 
coverage of less than 3%. Among respondents, 62% had psoriasis alone, while 38% also had 
psoriatic arthritis. 127 
Using the WHO definition of metabolic syndrome, a retrospective study compared records 
of 581 adults hospitalized with chronic moderate to severe plaque psoriasis with those of 
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1,044 hospitalized controls without psoriasis. The patients with psoriasis had chronic plaque 
disease requiring hospitalization because of the severity of their disease or treatment 
resistance. The median duration of psoriasis was 13 years for men and 16 years for women. 
Metabolic syndrome was found in 4.3% of the chronic plaque psoriasis patients and only 
1.1% in the control group. These psoriasis patients were at significantly increased risk for 
type 2 diabetes, hypertension, dyslipidemia, and coronary heart disease, and were also more 
likely to consume alcohol and to be smokers than controls. 128                 
Another case-controlled study compared 338 adult patients with psoriasis and psoriatic 
arthritis and 334 patients with non-psoriatic skin diseases to see if metabolic syndrome was 
more common among the former. In this study, the mean age of patients was 62.1 years in 
the control group and 63.8 years in the psoriasis group, and more persons in the psoriatic 
diseases group were smokers. Fifty five percent of psoriasis patients had BSA ≥ 10%, 43% 
had PASI scores ≥ 10. 129  In a retrospective case-control study, information from the 
database of a large managed care organization, with approximately 3.8 million members, 
was used to assess the potential association between metabolic syndrome and psoriasis. In 
total, nearly 17,000 patients with psoriasis and 49,000 controls were included; about half 
were women. The proportion of patients with conditions associated with metabolic 
syndrome, such as diabetes mellitus, hypertension, and obesity, were increased in those 
with psoriasis versus controls. Triglyceride and total cholesterol levels were also higher in 
the psoriasis group by a small but significant amount. 130 
7.3 Diabetes 
The association of psoriasis with obesity and diabetes is implicitly evident with the data 
presented under metabolic syndrome. In a population-based observational study using 
the UKGPRD, the electronic records of about 73,000 patients were examined between 1994 
and 2005. The group was matched between those with a first-time diagnosis of psoriasis and 
those without. Analysis showed that, as compared to those without psoriasis, the odds ratio 
(OR) of developing diabetes mellitus in those with psoriasis was 1.31. This odds ratio was 
corrected for smoking status, body mass index (BMI), hyperlipidemia, infections, and 
systemic steroid use. Among overweight patients (BMI=25), the OR of developing diabetes 
mellitus, as compared to normal weight patients, was 7.04 among overweight patients 
without psoriasis, but this OR was elevated to 8.27 among overweight patients with 
psoriasis. The risk of developing diabetes mellitus in the psoriasis cohort appeared 
independent of BMI. Specifically, the risk for developing diabetes mellitus in psoriatic 
patients of normal weight, or BMI less than 25, increased twofold, 2.02, compared with 
normal weight patients without psoriasis. 131  
To evaluate further the potential relationship between obesity and psoriasis, Setty and 
colleagues conducted a prospective, 16-year longitudinal study that evaluated the 
relationship between adiposity and incidence of psoriasis in a prospective cohort of nearly 
117,000 female registered nurses who were between the ages of 25 and 42 years and who 
had no previously diagnosed psoriasis. The study investigators measured body mass 
index (BMI), weight change, waist circumference, hip circumference, waist-hip ratio, and 
incident psoriasis. Data were collected in 78,626 women and in the study time period, 892 
newly diagnosed cases of psoriasis were identified. Using a BMI of 21.0 to 22.9 as the 
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reference, the relative risk of psoriasis increased significantly as the BMI increased in all 
three evaluations: updated, baseline, and after18 years. In the baseline evaluation, the 
relative risk for the 30.0-34.9 BMI range was 1.73, rising to 2.23 when the BMI was greater 
than or equal to 35. For the updated evaluation, which was updated every 2 years during 
follow-up, the relative risk was 1.48 in the 30-34.9 BMI range, and 2.69 when the BMI was 
over 35. Additionally, a BMI value under 21 was associated with a lower psoriasis risk. 
Taken together, these data show that multiple measures of adiposity, such as BMI, weight 
gain since the age of 18, and waist and hip circumference, are substantial risk factors for 
the development of psoriasis. 132 
Using the same study that began in 1989, Qureshi and colleagues published data on the risk 
of diabetes and hypertension in female patients with psoriasis. Out of 84,039 women who 
responded to a questionnaire in 2005 regarding psoriasis, 5,978 women were excluded due 
to reporting diabetes or hypertension at baseline. Out of the remaining 78,061 women, 1,813 
reported a lifetime history of physician-diagnosed psoriasis. During the 14-year follow up 
from 1991 to 2005, 1500 incident cases of diabetes occurred in the group without psoriasis 
and 60 incident cases of diabetes occurred in the group with psoriasis. Of those that did not 
have psoriasis, there were 15,338 incident cases of hypertension and 386 incident cases of 
hypertension in the group that reported psoriasis (excluding any individuals with 
concomitant diabetes and hypertension). Mean BMI, alcohol intake, and proportions of 
current and past smokers were higher in the psoriasis group. There was no difference in 
mean age between the groups with and without psoriasis. Concomitant psoriasis therapies 
were unknown. 133 
7.4 Chronic Obstructive Pulmonary Disease (COPD) 
More recently Chiang & Lin looked at the National Health Insurance database in Taiwan 
from 2004 to 2006. The risk of COPD was compared between patients with psoriasis and a 
matched reference cohort. Their study included 2096 patients with psoriasis and 8384 
randomly selected subjects. After adjusting for sociodemographic characteristics and 
selected co-morbid medical disorders, results showed a hazards ratio (HR) of COPD for 
mild psoriasis (defined as those just getting topical therapy) to be 2.22. Patients in the 
comparison cohort with severe psoriasis (defined as those under phototherapy or systemic 
medication) had an HR of COPD of 2.81. Analysis stratified by patient age and gender 
showed an adjusted HR for COPD occurring during the 18-month follow-up period to be 
2.19 times higher for patients with psoriasis who were > 50 years old than for the same age 
group of the comparison cohort. There was no significant difference in patients ≤ 50 years 
old. In male subjects, the adjusted HR of COPD during the follow-up period was 2.38 times 
greater for those with psoriasis than those without; however, there was no significant 
difference in the female group. This study places a distinct association among male patients 
with severe psoriasis, especially those over 50 years of age and psoriasis.134  
7.5 Venous thromboembolism 
Using the multivariate Poisson regression model controlling for age, gender, comorbidity, 
concomitant medication, socio-economic data and calendar year, Ahlehoff et al looked at 
data from a Danish nationwide cohort derived from records of hospitalization, drugs 
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dispensing from pharmacies, socio-economic data, and listed causes of death. The intent 
was to look at the risk of venous thromboembolism (VTE) in patients with psoriasis. A total 
of 35,138 patients with mild psoriasis and 3,526 patients with severe psoriasis were 
identified, and compared with 4,126,075 controls. The rate ratio (RR) for VTE was elevated 
in all patients with psoriasis, with RR 1.35 for mild psoriasis, and RR 2.06 for more severe 
disease. Excluding patients with malignancies and undergoing surgery did not alter results. 
There was a highest risk noted in young patients with severe psoriasis.135  
7.6 Pregnancy 
Pregnant women with psoriasis (n = 47) and non-pregnant controls (n = 27) were assessed 5 
times over 1 year at approximately 10, 20, and 30 weeks of pregnancy and 6 and more than 
24 weeks postpartum. A change of more than 3% body surface area defined “Improvement” 
and “Worsening”; no change was defined as a change in body surface area between 3% and 
-3%. Most pregnant women with psoriasis experienced improvement in psoriasis or no 
change during their pregnancies. Psoriasis worsened in fewer than one-fourth of the 
patients. Conversely, nearly two-thirds of the patients experienced worsening of their 
psoriasis postpartum. 136  Retrospective examination of psoriasis data from 358 women with 
psoriasis and 131,424 without psoriasis indicates that psoriasis may be associated with poor 
pregnancy outcomes, including: spontaneous abortion risk ratio (RR) 3.90; preterm birth RR 
2.92; severe pre-eclampsia and eclampsia RR 4.92; placenta previa with/without hemorrhage 
RR 3.49; and ectopic pregnancy RR 4.56. 137 Many of the treatments to be discussed later 
need to be avoided in the pregnancy state. 
7.7 Celiac disease 
The association between psoriasis and celiac disease has already been mentioned. Patients 
with psoriasis often have increased serum levels of IgA antibodies to gliadin. Out of 302 
patients with psoriasis, 16% (18 females and 31 males) showed serum IgA  
Anti-Gliadin A (AGA) levels above the 90th percentile value (51 u/ml) of the reference 
group. Palmoplantar pustulosis was found more often than other types of psoriasis. Some 
patients had signs of gluten sensitive enteropathy. It is noteworthy that 10% of patients with 
celiac disease fail to show AGA. 138  Out of 33 AGA-positive patients with psoriasis patients, 
15 had an increased number of lymphocytes in the duodenal epithelium, and two had IgA 
antibodies to endomysium (EmA). Thirty of the 33 patients with AGA completed a gluten-
free diet for a trial period, after which they showed a highly significant decrease in mean 
PASI. Resumption of a regular diet resulted in a return of pre-study psoriasis. 139 
7.8 Malignancies 
Using the UKGPRD populations of 153,197 from 1988 ton 2002, patients with psoriasis 
(including 3994 with severe psoriasis) and 765,950 matched controls were identified for a 
retrospective cohort analysis. Psoriasis patients were classified as severe if they received a 
systemic treatment. It is important to note that the disease severity classification was based 
on the treatment the patient had received. The potential causal relationship between therapy 
and risk of malignancy was not addressed in this study. Highest risk was noted on the 
occurrence of T-cell lymphoma among the severe psoriasis population. 140 
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Adjusted Relative Risk (RR, 95% CI)* Mild Psoriasis Severe Psoriasis 
All lymphoma 1.34 (1.16, 1.54)† 1.59   (0.88, 2.89)‡ 
Non-Hodgkin’s lymphoma £ 1.15 (0.97, 1.37)‡ 0.73   (0.28, 1.96)§ 
Hodgkin’s lymphoma 1.42 (1.00, 2.02)** 3.18   (1.01, 9.97)** 
T-cell lymphoma 4.10 (2.70, 6.23)† 10.75 (3.89, 29.76)† 
*RR = relative risk( confidence interval), adjusted for gender and age 
†   P <0.001 
‡   P <0.1 
§   P = 0.5 
** P = 0.05 
£  Excludes cutaneous T-cell lymphoma 
(Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB. The risk of lymphoma in 
patients with psoriasis. J Invest Dermatol. 2006;126:2194-2201.) 
Table 3. Risk of Lymphoma in Psoriasis (UK General Practice Research Database) 28 
A study in Sweden examined records of patients with a hospital discharge diagnosis of 
psoriasis between the years of 1965 and 1983, and identified 9,773 patients who were alive 
and free of cancer one year after admission. Relative rates of cancer were compared to the 
Swedish national population by computing the standardized incidence ratios (SIR). The 
table gives the SIR for different cancer types. The most commonly seen cancers were 
prostate in men (77 cases) and breast in women (78 cases). Other common cancers were lung 
(65 cases in men, 25 in women), colon (26 cases each in men and women), and squamous cell 
cancer of the skin (35 cases in men,10 in women). An increased risk of squamous cell cancer 
was seen in all anatomic regions except the head and neck. However, no increased risk of 
melanoma was seen with psoriasis. 141 
 
SIR (95% CI) Male Female Both Genders 
Oral/Pharyngeal 2.60 (1.68-3.84) 3.37 (1.68-6.04) 2.80 1.96-3.87) 
Esophagus 3.00 (1.59-5.13) 3.03 (082-7.76) 3.01-1.75-4.81) 
Liver 2.52 (1.49-3.98) 1.36 (0.68-2.44) 1.91 (1.28-2.74) 
Pancreas 1.34 (0.73-2.24) 1.82 (0.99-3.05) 1.56 (1.02-2.23) 
Lung 1.91 (1.48-2.44) 3.00 (1.94-4.43) 2.13 (1.71-2.61) 
Skin, Squamous Cell 
Carcinoma 
2.75 (1.92-3.83) 1.92 (1.02-3.28) 2.46 (1.82-3.27 
Genital organs 2.69 (1.16-5.30) 2.47 (0.90-5.37)  
Kidney, pelvis 1.10 (0.58-1.88) 2.45 (1.37-4.04) 1.56 (1.04-2.25) 
Mycosis fungoides 26.7 (8.60-62.3) 0.07 (0.51.3) 19.3 (6.22-45.1) 
Non-lymphocytic 
leukemia 
1.74 (0.64-3.79) 2.18 (0.70-5.09) 1.92 (0.96-3.43) 
* Incidence ratio of select neoplasms among patients hospitalized for psoriasis 
Boffetta P, Gridley G, Lindelof B. Cancer risk in a population-based cohort of patients hospitalized 
for psoriasis in Sweden. J Invest Dermatol. 2001;117:1531-1537. 
Table 4. Prevalence of Malignancies in Psoriasis * (Swedish Hospital Study) 28 
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A cohort US study assessing incidence of cancer in 1,105 patients with severe psoriasis and 
16,519 patients with less severe psoriasis looked at patients in the government public 
assistance program of three states from July 1992 to March 1996. One state was located in the 
mid-Atlantic region, one in the midwest, and one in the southern region of the US The states 
were not identified. The incidence of cancer in the psoriasis population was compared with 
the general population (N=259,808). Margolis et al designed a 4-year retrospective cohort 
study using Medicaid data from three large states to compare the risk of malignancy among 
adult patients ≥ 20 years with severe psoriasis treated with ≥ 1 systemic agents and less 
severe psoriasis not treated with a systemic agent. Comparison groups included patients 
with hypertension, patients with severe eczema, and organ transplant recipients. The 
hypertension group was selected as the reference group because the cancer risk among 
hypertensive persons is not expected to be substantially different from the risk in the 
general population. 
Patients with severe psoriasis were more likely to develop a malignancy than those patients 
in the hypertension, severe eczema, and less severe psoriasis groups. 
Patients with less severe psoriasis may have had a slightly increased risk of developing 
cancer compared with the hypertension group. A limitation of this study is that it did not 
differentiate between potential causes for increased risk of cancer: psoriasis severity and 
systemic agent use. 142 
 
Relative Rate Ratio (RR, 95% CI)* Less Severe Psoriasis Severe Psoriasis † 
All malignancies 
 
1.13 (1.03-1.25) 1.78 (1.32-2.40) 
Lymphoproliferative malignancies 2.11 (1.63-2.74) 7.95 (4.94-12.79) 
Skin malignancies (non-melanoma & 
unknown behavior 
2.35 (1.96-2.82) 4.15 (2.52-6.84) 
Malignancies( excluding non-melanoma 
skin and lymphoproliferative 
malignancies 
1.00 (0.90-1.12) 1.46 (1.04-2-05) 
* Poisson regression used to estimate relative rate ratio compared with hypertensive population 
adjusted for age, patioent’s state of origin, and sex. 
† Psoriasis patients were classified as severe if they received treatment with systemic medications. 
Margolis D, et al. Arch Dermatol. 2001;137:778-783. 
Table 5. Prevalence of Malignancies in Psoriasis (US  Study) 
7.9 Management of psoriasis & psoriatic arthritis 
Studies looking at cognitive behavior therapy as an adjunct to pharmaceutical therapies in 
patients with psoriasis showed clinical improvement in comparison to patients receiving 
pharmacological therapy alone. 143 High levels of worry and stress have been found to 
aggravate disease activity, and aggravate the therapeutic benefit of Psoralen and UVA 
therapy (PUVA). 144 Attempts to look at diet including diets rich in zinc, 145 and turkey meat, 
146 diets low in tryptophan, 147 protein, 148 or calories 149  seem to have little impact. As 
mentioned before, in patients with both celiac disease and psoriasis, diets low in gluten have 
been shown to be useful in improving both conditions. 28 
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It is well documented sunlight exposure (heliotherapy), and spa treatments such as those in 
the Israeli Dead Sea can be beneficial. 150 
Traditionally, pharmacological therapy has been divided into topical therapy, systemic 
therapy and photo-pharmacological therapy (PUVA). Some include all forms of 
phototherapy in systemic therapy. Before steroids were introduced, topical therapy was 
limited to tar, anthralin and keratolytics like urea and salicylic acid. The impossibility to 
standardize biological activity on tar products, and arrive at a consensus on measuring 
disease severity to gauge therapeutic success has hindered the ability to define and compare 
various reported efficacies of these topical regimens. 
7.10 Tar with & without UV therapy 
Tar had been used as topical monotherapy for a century before it was combined with 
Ultraviolet B (UV-B at 290-320 nm) in the Goeckerman regimen. 151 Crude coal tar (2.5-5%) 
was applied daily in combination with a tar bath and UV therapy, usually as an inpatient 
facility. It became clear UVB was more valuable than UVA. 152 In addition, tar could 
sensitize the skin to UVA, but not UVB. It is believed UVB erythema thresholds prevent 
UVA exposure sufficient to cause photosensitization in the Goeckerman regimen. 153 The 
risk from therapeutic tar is small. 154   155  It may be wise to avoid prolonged application to 
the anogenital areas including the scrotum, and avoid prolonged UV exposure. 156  157  158  159 
7.11 Anthralin (dithranol) 
Chrysarobin, from the bark of a tree, was found to be useful in the treatment of psoriasis. 
Dithranol, a synthetic derivative, was found to be unstable, but salicylic acid was found to 
stabilize it and lead to the development of the Ingram regimen. 160  After a tar bath, followed 
by UVB, the lesions were covered with dithranol paste in increasing concentrations seeking 
a maximum response while avoiding irritation. The regimen became popular in Europe. It 
was later found use of dithranol in Lassar’s paste was equally effective. Short contact 
dithranol therapy – twice daily and in high concentration regimes, was also effective. 161  
Newer formulations have been developed to limit staining and reduce irritation. In some 
parts of the world, anthralin is available as a combination preparation with potent topical 
steroids, and effective results have been seen. 162 
7.12 Topical corticosteroids 
Held by many as the topical treatment of choice, several preparations are widely available 
worldwide. The more potent forms of topical corticosteroids, are needed to treat 
hyperkeratotic plaques, and difficult to treat areas like the scalp, hands and feet. Besides 
their direct effect in limiting psoriasis, these agents are helpful in reducing symptoms like 
pruritus, and limiting irritation caused by other therapies. Better results are often obtained 
using occlusive dressings; a recent study found even better effectiveness when occluded 
with a hydrocolloid dressing. 163 Cutaneous side effects include telangiestasias, atrophy and 
striae. 164  Besides cutaneous adverse events adrenal suppression leading to lowering plasma 
cortisol levels can be observed with the most-potent preparations. 165 As little as 7 g/day of 
0.05% clobetasol propionate or 0.05% betamethasone dipropionate was sufficient to 
suppress morning plasma cortisol levels in 20% of patients. 166 Tolerance or tachyphylaxis is 
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not uncommon. To avoid this, as well as other adverse side effects, sequential therapy 
incorporating other topical agents, and pulse therapy rotating the various agents, have been 
implemented limiting total contact with skin, and any significant absorption. 167  168  169 
7.13 Intralesional corticosteroids 
Resistant and thick plaques in awkward anatomical areas, like the knuckles, where it is 
difficult to keep topical preparations during daily living activities, often respond to 
intralesional injections with triamcinolone acetonide with remarkable success.  
7.14 Vitamin D analogs 
Naturally occurring and synthetic vitamin D analogues have been found to be effective in 
the topical treatment of psoriasis. Vitamin D3  and its active metabolite, 1,25 
dihydroxyvitamin D3, (calcitriol), as well as the three synthetic analogues – calcipotriol 
(known in the US as calcipotriene), 1-24-dihydroxyvitamin D3 (tacalcitol), and 1,25-
dihydroxyvitamin D3  (maxacalcitol). Calcipotriol ointment is the most widely prescribed 
vitamin D analog. The mechanism by which these molecules affect their therapeutic benefit 
has already been described in a previous section. Current concern on their use includes 
irritation, and the potential for hypercalcemia, which has not been observed with the use or 
recommended maximum topical dosing of up to 100 g/week. 170 Ointment preparations 
appear to be more effective than the others available. A combination stable formulation 
using calcipotriol 50 μg/g and betamethasone diproprionate 0.5%mg/g, applied once daily 
shows better results than either product alone. 171  Calcitriol ointment 3 μg/g has shown 
long term effectiveness in the treatment of chronic large plaque psoriasis. Comparison 
between this agent, calcipotriol and other topical agents used to treat psoriasis show unclear 
results except for the superiority of calcitriol in the treatment of face and flexural regions, 
and a lower relapse rate following withdrawal compared with topical steroids. 172    173 
Tacalcitol 4 μg/g ointment is effective in the treatment of chronic plaque psoriasis, but does 
not appear to show superiority to calcipotriol 50 μg/g. 174 Preliminary studies indicate 
maxacalcitol applied once daily may be more effective in    short-term studies than 
calcipotriol 50 μg/g. 175 
It is important to note salient interesting interactive relations when considering use of 
vitamin D analogues. Use of calcipotriol 50 μg/g used in combination with methotrexate 
allows the use of lower doses of methotrexate. 176  Clinical and in vitro studies have been 
performed analyzing the compatibility of using clobetasol propionate spray or lotion 
together with calcitriol ointment 3 μg/g. Results suggest calcitriol remains stable in the 
presence of each of the other compounds. The sequence used was not relevant to their 
continued efficacy. 177 178 
Calcipotriol ointment enhances the efficacy of PUVA and UVB therapy, Howeverr, UVA 
partly inactivates calcipotriol, while UVB serves to absorb calcipotriol. When used with 
phototherapy, these products should be applied after the UV therapy session. 28 Tacalcitols 
ointment when combined with PUVA is UVA sparing, 179 while calcitriol is UVB sparing 
when used in combination. 180 
When used in combination with topical steroids, vitamin D analogs offer the advantage of 
sustained efficacy while offering a desirable steroid sparing effect. 181 This has lead to a wide 
www.intechopen.com
 Psoriasis – A Systemic Disease 
 
184 
range of pulsing and sequential therapy regimens with anecdotal reports attesting to their 
efficacy. Controlled corroborating studies are lacking. 
7.15 Vitamin A analogs 
Retinoids have been suspected to be a successful alternative to the treatment of psoriasis. 
With their direct effect on cellular proliferation and subsequent differentiation, it would be 
expected they would be the ideal preparation. Initial trials revealed efficacy, but significant 
irritation. 182 The development of the products that selectively used the retinoid acid 
receptor ushered in tazarotene, a synthetic retinoid, whose main metabolite binds the RARs 
ǃ and Ǆ. 183 Applied as its 0.05% or 0.1% gel once daily for three months, showed significant 
improvement over its gel vehicle in the treatment of chronic plaque psoriasis. 184  Irritation 
was its principal drawback, which was reduced when the 0.05% and 0.1% creams were 
introduced. 185 Reports using a topical steroid helped maintain a longer standing remission, 
while reducing some of the irritation. 186 
7.16 Topical calcineurin inhibitors 
The two products in this category currently available are tacrolimus and pimecrolimus. 
Developed initially for the treatment of childhood atopic dermatitis, both preparations have 
been found effective for the management of psoriasis involving the face, neck, flexular areas, 
the genitals and mucosal surfaces. They have a safer profile than topical steroids, and do not 
produce skin atrophy where used. 187 
7.17 Phototherapy  
7.17.1 UVB 
The Goeckerman regimen, which used UVB was already described  188 Subsequent to the 
time this treatment was being offered, it was learned that broad band UVB at 290-320 nm 
(BBUVB) alone was effective in clearing psoriasis 189 190  191  192 and even as effective as PUVA 
193  While some studies have not shown an increased rate of skin cancer risk in UVB treated 
psoriasis patients   194  195  196, suspicion still exists that long term exposure may contribute to 
total risk. One study does suggest an added risk for genital tumors in men treated with 
BBUVB, 197 making it prudent to protect that area during treatment. More recently, a 
narrow-band source of UVB at 311nm, (NBUVB) has offered longer remissions, and 
suggested a lower incidence of burning. 198    199   200   Studies comparing a higher intensity 
(100W) NBUVB have suggested better results still. However, when compared to PUVA 
several studies provide conflicting results suggesting patient selection, level of disease 
activity, and need for larger population studies are needed before reliable results can be 
compared. 201   202    203   Data showing a lower risk for UV carcinogenesis is limited to one 
study, which failed to reveal significant association between NBUVB and squamous cell 
carcinoma, malignant melanoma and basal cell carcinoma. 204 One observation peculiar to 
NBUVB, which has not been observed in BBUVB, is the occurrence of painful blisters at the 
site of psoriatic lesions appearing in the middle of the treatment course. They are self 
limiting, but can be painful and require a brief interruption in the regimen. 205 Both NBUVB 
and BBUVB units are commercially available for home therapy.  
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In addition, end results can often be improved by supplementing phototherapy with topical 
dithranol, and oral retinoids, Heliotherapy, described previously, enjoys the therapeutic benefit 
of the full-range light spectrum of the sun. A retrospective study looked at 1488 psoriasis 
patients treated at a Dead Sea Clinic from 1983 to 1986. Patients were treated by sun exposure 
and bathing in the mineral-rich sea. Nearly three quarters improved by 90% or more. 206  
UVB can be used effectively for the treatment of guttate psoriasis, as well as those relatively 
rare forms of head and neck or “seborrheic” psoriasis. It is also helpful in patients who live 
in colder climates and experience seasonal exacerbation during winter months. UVB can 
also be used as adjunct therapy for a temporary period for patients who have responded to 
systemic therapy, but experience an unexpected setback in disease activity. Skin types 
should always be considered, especially if long-term care is a reasonable expectation, due to 
the potential for UV related carcinogenesis. This risk would be theoretically greater on 
individuals of Fitzpatrick skin types I-III.  
7.18 Psoralen photochemotherapy (PUVA) 
Success with the Goeckerman regimen, and use of psoralen photochemotherapy lead to 
thinking it might help psoriasis. 207  208  By the early 1970’s, there was ample evidence 8-
methoxypsoralen (8-MOP) and UVA would treat psoriasis effectively, and thus lead to the 
treatment definition of photochemotherapy. 209  PUVA soon became its modified acronym. 
Other forms of psoralen like 5-methoxypsoralen (5-MOP) and trimethylpsoralen have been 
used with similar results as 8-MOP. 210  211  
The treatment essentially involves the ingestion of one of several preparations of 8-MOP 
available at the recommended calculated dose. Bioavailability varies from various 
preparations, and from patient to patient. Intestinal absorption is affected by fat content. It is 
customary to use one preparation, take it on an empty stomach and insist on a constant time 
interval from ingestion to UVA exposure. Dose calculation based on weight is 0.6mg/kg 
given 2 hours before irradiation. Patients must wear appropriate eye protection for a period 
of 24 hours from the time the psoralen is ingested to prevent sun-induced cataracts. 
Treatment is given 2-4 times weekly. Initial UVA dose is based on skin type and is 
incrementally increased with each treatment by 0.5-1.5 J/cm2 each time. 212 Once remission is 
achieved the frequency of treatment is gradually reduced and given every 1-4 weeks. Patient 
selection is important. Individuals must have physical stamina to stand for prolonged 
periods of time during the irradiation sessions. Previous exposure to arsenic, prior radiation 
therapy, pregnancy, and ingestion of medication that is photosensitizing are all 
contraindicated. Persons less than 18 years of age should not receive PUVA. Persons with 
any medical condition that can be exacerbated by UV exposure including patients with 
collagen vascular disease should be identified.  
Clearance rates topping 90% have been reported, with substantial clearance being achieved 
with 15-25 treatments. 213  214   215    216  217  PUVA can be helpful in erythrodermic psoriasis, 
psoriasis involving palms and soles, pustular psoriasis, and psoriasis involving the nails. 
Results in these resistant forms of disease vary, and are not as successful. PUVA can be 
combined with dithronol, 218 methotrexate, 219 and calcipotriol.220 Risk of cancer is increased 
further with concomitant methotrexate use. 221 Calcipotriol use reduces the required the 
UVA exposure, and as mentioned previously, should be used after irradiation to prevent its 
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inactivation. PUVA and UVB have been used effectively in patients who fail to response to 
PUVA or UVB alone. 222 Topical PUVA offers similar therapeutic advantage with fewer side 
effects. It is not generally available to the individual patient requiring in-patient 
administration, and thus too costly for practical use. 
Early reports raised the concern that PUVA treated patients would experience an increased 
rate of developing tumors in patients with xeroderma pigmentosa. 223  PUVA appeared to 
have a promoter effect on patients previously exposed to X-irradiation, arsenic, and several 
cytotoxic drugs. 224  Subsequent studies have corroborated the same association with 
patients receiving PUVA. The risk is most profound on patients of fair skin. 225 226 Stern et al 
reported an increase rate of squamous cell carcinoma among patients that received PUVA 
for a prolonged period of time. No association was found with malignant melanoma or 
basal cell carcinoma. 227  In a further follow-up study, the same group identified a risk for 
melanoma in association with long-term exposure to PUVA. 228 Subsequent Swedish study 
found a similar association with squamous cell carcinoma but no association with malignant 
melanoma or basal cell carcinoma. 229 Until more definitive studies define the proper course, 
current prudence suggests to avoid using PUVA on patients with family or past medical 
history of malignant melanoma, and to those that have already received 200 treatments. 230 
8. Systemic therapy 
Systemic therapy is reversed for the more severe forms of psoriasis and the treatment of 
psoriatic arthritis. For the latter a Disease Modifying Anti Rheumatic Drug (DMARD) is 
generally used with the double aim of arresting inflammation, and halting disease 
progression. Some systemic agents can treat PsA while others do not.  
8.1 Methotrexate (MTX) 
An initial observation in 1951 demonstrated that aminopterin was beneficial in the treatment 
of psoriasis, and led to exploring use of its more stable analogue methotrexate,  which can 
be administered orally, intramuscularly, subcutaneously and intravenously.231 Its oral 
absorption may be impeded in psoriatic patients. 232  Twenty to 70% of methotrexate is 
bound to plasma albumin, 233  234  235 and excretion is largely by the kidney, but there is 
extensive entero-hepatic cycling. 236  237 238  Initially its mechanism was felt to be its anti-
metabolite effect on keratinocyte proliferation through competitive inhibition of 
dihydrofolate reductase in DNA synthesis, 239 More recently, it has been learned that at low 
doses (0.1 to 0.3 mg/kg weekly), a dose too low to affect keratinocytes, methotrexate is 10-
100 times more effective in inhibiting proliferation of lymphoid cells through its inhibition 
of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase leading to accumulation 
of extracellular adenosine, which has anti-inflammatory activities including slowing 
chemotaxis of polymorphonuclear leukocytes. 240  241  242  These latter two mechanisms may 
have a greater effect on its ability to treat psoriasis. Addition of folic acid supplementation 
(1-5 mg/day) reduces the side effects of nausea, oral ulcers, and megaloblastic anemia.  
Controlled trials attest to the effectiveness of methotrexate for the treatment of psoriasis. 243   
244 Initially 5-10 mg is given orally once a week to avoid early toxicity (the elderly can be 
started often with 2.5 mg). Doses can be increased by 2.5 mg/week to achieve a maximum of 
25 mg/week. 245  Clinical response is generally noted within 2 weeks. Pustular psoriasis and 
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psoriatic erythroderma tend to respond to this regimen. Transient anorexia, nausea, and 
other upper gastrointestinal symptoms are the most common symptoms.  
Before treatment, baseline renal, hepatic, and marrow function should be obtained. The 
presence of chronic hepatitis (B and C) should be ruled out. Due to methotrexate’s direct 
effect on the immune system, latent tuberculosis, 246 and, where geographically appropriate, 
chronic fungal and other parasitic infection should be ruled out as well. 247Since standard 
serum liver function tests cannot evaluate hepatic damage reliably, current guidelines 
suggest a liver biopsy be performed when a cumulative dose of 1.5 g is achieved, and 
repeated every 1.0-2.0 g thereafter. A liver biopsy has been the preferred method of 
monitoring the damaging effect of methotrexate, since serological liver function studies 
have been known to conceal evolving harm, and reveal significant hepatic scarring only too 
late in the course of therapy.248  Hepatotoxicity is a well established effect of methotrexate. 
249  250  Renal impairment, previous intake of hepatotoxins, and alcohol use can increase this 
risk  251  In some parts of the world monitoring amino terminal type III procollagen peptide 
(PIIINP) assay every three months is being done in lieu of liver biopsy. In the US, the FDA 
has not approved the use of this assay yet. 252 
Myelosuppression is a serious issue with the use methotrexate. It can occur 7-10 days after 
an initial dose is given. It can also be seen in the setting of folate deficiency, as an initial 
response in the beginning of therapy, due to toxicity, or quite innocently when the patient 
receives sulfonamides or other drug (usually a sulfa based agent) interfering with 
dihydrofolate reductase activity. This is a potentially fatal reaction, and must be identified 
and treated with folinic acid given at a dose 20 mg. parenterally or orally, and repeated 
every 6 hours. 253 
There is no evidence that splitting the dose in three parts, and giving it every 12 hours, a 
practice that was common to synchronize the therapy to the keratinocyte cell cycle when it 
was believed the treatment was all about epidermal cell turnover, offers any advantage over 
single weekly dose, except when it comes to reducing nausea. Pharmacokinetic studies 
indicate the bioavailability of MTX after oral ingestion is highly variable and unreliable.254  
Subcutaneous administration offers the same advantage as intramuscular. Compared with 
the highly variable and unpredictable bioavailability following oral administration (25–
80%), parenteral dosing achieves more consistent and complete absorption. 255 
Intramuscular or subcutaneous administrations achieve equivalent pharmacokinetic profiles 
with a bioavailability of 87% of that following intravenous dosing. 
Concern exists over the possible development of malignancies while on long-term therapy 
with methotrexate. Evidence supports an increase risk for developing cutaneous 
squamous cell carcinoma in those with cumulative doses in excess of 3 g over 4 years. 
Thus risk was independent of PUVA. Pneumonitis, oligospermia, and osteopathy can 
occur. The latter can be confused with psoriatic arthritis  256 Methotrexate is teratogenic, 
and an abortifacient in early pregnancy. 257 Conception is regarded safe 3 months after 
discontinuation of therapy. 258  
Methotrexate has been used in combination with UVB, PUVA,  259 and systemic retinoids.260  
Use with the latter must be done with caution due to greater risk of hepatitis. Methotrexate 
and cyclosporine helps patients with psoriatic arthritis 261, while combining methotrexate 
with colchicine has been used in generalized pustular psoriasis. 262 
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8.2 Cyclosporine 
Used principally as an immune-suppressant in organ-transplant recipients, cyclosporine is a 
cyclic undecapeptide derived from the fungus Tolypocladium inflatum gams. It was found to 
clear psoriasis in 1979. 263 Its mechanism of action is presumed to be related to its inhibitory 
effect on T-cell activation. 264  Because of it toxic effects, and its potential to cause 
malignancies, its use is generally limited to patients that have failed other systemic 
alternatives. Exclusion criteria for its use include renal dysfunction, uncontrolled 
hypertension, past or present malignancy, epilepsy, acute infections, other 
immunosuppressive therapy, concomitant therapy with neurotoxins, previous serious side 
effects from prior use, or known hypersensitivity. Candidates for using cyclosporine must 
be reliable to undergo proper frequent monitoring. As a highly lipophilic agent metabolized 
in the liver by means of the cytochrome P-450, there are many drugs that could interact with 
cyclosporine such as anticonvulsants, which can prevent therapeutic levels of cyclosporine. 
NSAIDs (non-steroidal anti-inflammatory drugs) may enhance nephrotoxicity. 265 The 
recommended initial daily oral regimen is 2.5 mg/kg divided in two doses. Improvement 
often starts in days, and failure to see any benefit in two weeks should warrant a dose 
escalation to a maximum of 5 mg/kg/day.266 Sudden withdrawal may lead to relapse, but 
nothing like the flares seen with systemic steroid withdrawal.267  268 Ideally, this should be 
limited to 3-4 months.269  270  In the US, the FDA recommends cyclosporine should be used 
for less than one year. One study compared intermittent cyclosporine with continuous use 
for psoriasis, and found an intermittent regimen was probably safer. 271 
Dose-related hypertension and nephrotoxicity are the most serious side effects associated 
with cyclosporine use. Blood pressure can increase sharply weeks after beginning therapy. 
Glomerular filtration rate may decrease while plasma creatinine levels may rise. Serum uric 
acid may rise prior to elevation in creatinine or blood urea nitrogen. Other side effects 
include gum hyperplasia, hypertrichosis, elevated sebum production, mild anemia, and 
paraesthesias. 272 The mechanism by which cyclosporine reverses the clinical signs of 
psoriasis is by blocking transcription and synthesis of lymphokines such as interleukin-2 
(IL-2) and interferon-y (IFN-y). 273  274  This product inhibits the accessory cell function of 
Langerhans cells, 275  decreases the capacity of dendritic cells to enhance mitogenic 
stimulation of lymphocytes, and induces secretion of thymic hormone. Thus, cyclosporine 
could inhibit cytokine-mediated cellular activation that may contribute to the pathogenesis 
and progression of this disease. 276   277 
Immunosuppression with long term use of cyclosporine may be associated with an 
increased risk for cutaneous malignancies, lymphomas. This is seen especially in patients 
with previous history of getting UV irradiation in any therapeutic regimen, or arsenic and 
methotrexate. 28  Females observed to develop cervical intraepithelial neoplasia, and 
males with HPV-associated penile carcinoma suggests the need for frequent cervical 
smears for females and examination for males especially when there is prior history of 
HPV infection. 278  279 
8.3 Oral retinoids 
Retinoids refer to a family of natural and synthetic derivatives of vitamin A. Their role in 
skin physiology has been long established enhancing epithelial differentiation. Deficiency 
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causes squamous metaplasia and cutaneous hyperkeratosis, while their presence in excess 
can lead to xerosis with cutaneous exfoliation, hair loss, bony abnormalities, liver toxicity, 
and abnormalities in serum lipids. Oral retinoids are also well known for their teratogenic 
effect. They have been found to have a protective effect in slowing down or preventing the 
progression and development of cutaneous neoplasms arising out of chronic sun exposure. 
280  281 282 While isotretinoin is the most widely known retinoid, used principally in the 
treatment of nodular acne and other forms of severe acne, and its successful use in the 
treatment of psoriasis has been documented, 283 other retinoids have been found more 
effective in the management of psoriasis. Because serum lipids are often elevated and 
hepatotoxic effects can occur with their use, proper monitoring is recommended.  
8.4 Etretinate 
First reported in 1975 to be useful in the treatment of psoriasis, 284 it was found effective for 
the treatment of psoriasis vulgaris, pustular psoriasis, 285 and erythrodermic psoriasis. 286    
Its use has been replaced by acitretin in most countries. 
8.5 Acitretin 
This retinoid is the main active metabolite of etretinate. It has decreased lipophilicity 
resulting from being a free acid as opposed to an ester as in the case of etretinate. Its half life 
is 50 hours compared to 80 days for etretinate, making it a more desirable drug. Several 
clinical trials confer on acitretin the same profile of efficacy as etretinate. 287  288  289  290   
However, acitretin has been found to convert to etretinate in an unpredictable number of 
patients, requiring female patients of child-bearing age who use to refrain from pregnancy 
for 2 years after discontinuation of the drug. Retinoids should not be used in children except 
for exceptional circumstances, nor in anyone with pre-existing hyperlipidemia or liver 
disease. In the US, general practice is not to use an oral retinoid for psoriasis on any female 
of child-bearing age. Though a very small percentage of patients on acitretin may acquire a 
toxic hepatitis (1.5%), histological sign of hepatic damage is not found. Oral dosing can 
begin at 10 mg daily and increment to an optimum dose of 50 mg/day. Lipids should be 
monitored, and patients cautioned about photosensitivity. 291 The combination of acitretin 
with PUVA appears superior to PUVA alone. 292  Similarly acitretin improves the efficacy 
of UVB. 293 
Acitretin may help reduce the risk of cutaneous neoplasia brought on by chronic 
phototherapy. For this reason, its use has been advocated on patients with other risk factors 
for skin cancer who have received extensive phototherapy. 28  294 
8.6 Systemic corticosteroids  
Despite the fact that the use of systemic corticosteroids has not been advocated for the 
treatment of psoriasis, the practice of intramuscular injections with triamcinolone acetonide, 
commonly used for reduction of itching, inflammation, arthralgias and related symptoms 
associated with psoriasis, eczema, and other dermatoses is recognized as an effective clinical 
practice by many clinicians. However, in the case of psoriasis, there is often a break through 
of symptoms with repeated treatments. Rebound can also result. This phenomenon occurs 
often when patients with psoriasis undergo surgery. Current practice among 
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anesthesiologists is to administer a stress dose of corticosteroid prior to surgery, leading to 
an observed marked improvement of the psoriasis while in the hospital and following the 
immediate post-operative period. A rebound is generally noted a few weeks afterwards 
prompting a visit to the dermatologist’s office. In spite of it all, systemic corticosteroids can 
be helpful in cooling down the skin during the erythrodermic phase of disease, especially if 
the treatment is supplemented with another systemic agent that can assist in bringing a 
remission. Systemic corticosteroids also have a place in the treatment of the von Zumbush 
reaction, 295 and the hyperacute polyarthritis  with potential for joint damage. Lability of 
disease with steroids is common, and often difficult to dispel. 296 Systemic corticosteroids 
have been helpful with concomitant use of methotrexate in the management of rebound or 
acute flares associated with the use of efalizumab. 297 
8.7 Other systemic agents used for the treatment of psoriasis 
8.7.1 Hydroxyurea 
Hydroxyurea is an antimetabolite used mainly for the treatment of chronic myeloid leukemia 
among other malignancies. It is converted to its active metabolite which blocks the conversion 
of ribonucleotides to deoxyribonucleotides by blocking the action of ribonucleoside 
diphosphate reductase, and thus inhibiting DNA synthesis in proliferating cells. 298 
It was first conceived to be used on psoriasis in 1969.299  Oral regimens are generally up to 
0.5 g three times daily for a minimum of 2 months before considering the treatment 
suboptimal. Principal side effects include bone marrow suppression, profound anemia, and 
thrombocytopenia. Macrocytosis and leucopenia are practically universal. It is teratogenic, 
making it essential to be avoided during pregnancy. However, it is less hepatotoxic than 
methotrexate with less gastrointestinal side effects, and also less effective with a satisfactory 
response rate of 45-80%. 300 301 302  It is generally used when other systemic agents have 
failed, especially methotrexate. Besides, it can be used in combination with methotrexate, 303  
cyclosporine, 304  and acitretin. 305  A drug related cutaneous vasculitis has been reported. 28  
306  Leg ulcers can occur, and are often difficult to manage. 307 
8.8 6-Thioguanine 
Closely related to 6-mercaptopurine, 6-thioguanine was shown to be effective in the 
treatment of psoriasis. 308  309  Its mechanism of action, as an antimetabolite, appers to be 
depletion of T-cells in the skin. The studies show remarkable efficacy in patients that had 
failed other systemic therapies. Oral regimens ranged in dose from 20 mg twice weekly to 
120 mg/day, and the duration averaged 15 months. 310  311  In one study 14 out of 18 patients 
experienced greater than 90% improvement. Increased liver enzymes and veno-occlusive 
disease of the liver may be seen. 312 
8.9 Fumaric acid 
German speaking countries in Europe enjoy the most experience with the use of this family 
of compounds for the treatment of psoriasis. The mechanism of action seems to suggest the 
ability of fumarates to inhibit nuclear binding of nuclear Kappa B and promoting the 
secretion of Th2 cytokines such as IL-10, found to be beneficial in treating psoriasis. 313  314  
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Preparations commercially available incorporate several salts. Fumaderm is one such 
preparation with a mixture of dimethylfumarate, and the calcium, magnesium and zinc salts 
of monoethylfumaric acid. These compounds are not yet approved for use in the US. After 
ingestion, dimethylfumarate is hydrolysed to monomethylfumarate – the main active 
metabolite. Clinical trials show efficacy. 315  316  317  Regimen includes starting at 30 mg/day 
orally building up over several weeks to a maximum dosage of 240 mg three times daily. 
Dyspepsia and diarrhea are common appearing in about two thirds of patients, and one 
third develop flushing. Lymphocyte counts fall in nearly all, and can drop to 50%. Though it 
is prudent to monitor renal and liver function, it is rarely impaired.  
9. Biologics – The latest modality 
The mechanisms by which biologic agents exert their therapeutic benefit have been 
reviewed in the immunopathophysiology section of this chapter, and illustrated in Figure 1. 
In the US as in Europe and most parts of the world, their use is relegated generally to the 
patients suffering with moderate to severe disease, with or without psoriatic arthritis.  
The Food & Drug Administration (FDA) approved the use of efalizumab in November 2003, 
and the European Medicines Agency (EMEA) in September 2004. This was one of several 
biologics approved for the treatment of psoriasis on the basis of favorable findings obtained 
from well-designed clinical trials. 318 Ongoing monitoring of sustained efficacy, tolerability, 
and possible side effects lead to the discovery of 3 newly diagnosed cases of progressive 
multifocal leukoencephalopathy. 319 In 2009, efalizumab was voluntarily withdrawn from 
the market by Genentech, its manufacturer. This unexpected experience underscores the 
importance of vigilance and careful monitoring when treating a medical condition with any 
immunosuppressant – biologics being no exception. 
Another issue that relates to the use of biologics is the emergence of loss of therapeutic 
response. This may occur as a temporary minor flare of disease activity in spite of 
continuing use. It may also appear as a nearly total loss of therapeutic activity. Though this 
can occur with any biologic currently being used to treat psoriasis, it has been shown to 
occur more often with the monoclonal antibodies. It has been postulated this is due to the 
development of neutralizing antibodies, as in the case of infliximab and adalimumab,  
which generally follows with a subsequent drop in therapeutic serum level of the biologic 
being used.320 Concomitant use of methotrexate at low doses has been shown to diminish 
chances of developing neutralizing antibodies. 321  Anti-adalimumab antibodies in 
rheumatoid arthritis patients have been recently reported to be associated with interleukin-
10 gene polymorphism. 322 IL 10 is a key cytokine in antibody formation, and its role has 
been implicated in other autoimmune diseases. Neutralizing antibodies have not been 
detected to etanercept to date. Loss of response to the TNFǂ antagonists may also occur 
independent of adequate serum levels and lack of detectable antibodies. One thing is clear, 
the mechanism of loss of response is not as simple as one is lead to belief by reviewing 
current literature. One observation held by canvassing opinion from multiple thought 
leaders is resistance to therapy tends to arise early in therapy, and rarely after a patient 
shows adequate response to an agent for several years (personal communication). Further 
studies, especially comparative studies are needed to clarify the pathogenesis of this 
phenomenon, and learn which treatment is most appropriate to any given patient. 
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Fig. 10. Immunopathogenesis & Target Therapy (Legend) 
New approaches to the treatment of psoriasis include targeted biologic therapies. Of those that 
been approved for marketing, the two major therapeutic classes are T-cell–targeted therapies 
(alefacept and efalizumab) and anticytokine therapies (anti–tumor necrosis factor [TNF] 
therapies): infliximab, adalimumab, etanercept, and a monoclonal antibody against 
interleukin-12 and interleukin-23 (ustekinumab). Efalizumab (which has been withdrawn from 
the market) is a chimeric monoclonal anti-CD11a antibody. It blocks the interaction of CD11a 
(lymphocyte-function–associated antigen -1 (LFA- 1)  with intercellular adhesion molecule 1 
(ICAM-1), leading to a disruption of the interaction between dendritic cells and T cells at tissue 
sites and in lymph nodes as well as blocking of immune cell binding to blood vessels. 
Alefacept is a human LFA-3 Fc fusion protein that blocks the interaction between CD2 on T 
cells and LFA-3 on antigen-presenting cells. It also induces antibody-dependent cytotoxicity in 
T cells bound to alefacept. At this point, anti-TNF strategies have three targeted therapies: a 
humanized chimeric anti–TNF-ǂ monoclonal antibody (infliximab), a fully human 
monocolonal anti–TNF-ǂ antibody (adalimumab), and a human p75 TNF-receptor Fc fusion 
protein (etanercept). Blocking of Il-12 and Il13 is achieved by means of antibodies targeting the 
common p40 chain of these cytokines. (CD=cluster designaton; FcR=Fc receptor) 
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Agent Efficacy Side effects 
Sulfasalazine 323 324 
(anti-inflammatory) 
57% of assessed patients in 
treated group showed 
marked improvement. 
  
Effective in psoriatic 
arthritis 
25% patients get Headches, 
nausea, vomiting 
oligospermia, prutitis, 
anemia   1-2 
Azathioprine  325  326 
(purine analog 
antimetabolite) 
No conclusive studies Bone marrow suppression 
Mycophenolate mofetil 
(purine antimetbolite)327  328  
329 
Effective but with limited 
experience  
GI and bone marrow 
Cytokines 
IL-10  330  331 
 
 
 
IL-4 332 
 
50% reduction in severity 
Short trials- 10 patients & 
28  patients 
 
More than 68% 
improvement in  
20 patients  
 
Mild anemia, decrease 
response in delayed-type 
hypersensitivity reaction 
Zidovudine  333 
 
Improvement noted in 
AIDS-associated psoriasis  - 
Of 19 evaluable patients, 
90% had partial (58%) or 
complete (32%) 
improvement 
Failed to improve 
associated arthritis, and 
long term relapses were 
common 
Somatostatin  334 
 
Liarozole (retinoic acid 
metabolism blockers) 335  336 
 
Small series of patients,  
 
Similar to other systemic 
retinoids, but rapid 
clearance from blood once 
discontinued 
Blood levels of somatostatin 
are inversely proportional 
to clinical response  
 
Teratogenicity, 
hyperlipidemias, and other 
muco-cutaneous symptoms 
Photodynamic therapy (5-
aminolevulinic acid 
followed by UVB 
irradiation) 337  338 
Small series of patients – 
not all sites respond to 
treatment 
Local pain at siote of 
therapy 
Lasers  
Carbon dioxide and pulsed 
dye laser 
 
Excimer laser (308 nm 
UVB) 339  340 
 
 
Insufficient data 
 
 
Effective especially when 
using high dose therapy 
with long remissions 
 
 
 
 
Potential for burning as 
with phototherapy 
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Oral calcineurin 
antagonists 
Oral tacrolimus 341  342 
 
 
 
Oral Pimecrolimus 343 
 
Oral tacrolimus can 
improve severe psoriasis in 
short term (10 weeks) 
 
Oral Pimecrolimus  showed 
similar results 
 
 
Paraesthesias, headache, 
elevation in serum 
creatinine, and blood 
pressure 
Table 6. List of Other Systemic Agents Less Commonly Used for Treating Psoriasis  
 
Biologic Alefacept
344 
Etanercept 345  
346 
Infliximab 347 348 Adalimumab 349 
350 351 352 
Ustekinumab 353  
354 
Dose & 
Route & 
duration 
15 mg. im 
weekely 
for 12 
weeks 
50 mg. sub cut 
2x/wk for 12 
weeks then once 
per week 
thereafter  
3-10 mg/kg IV 
infusion over 2 
hrs. at week 0, 2, 
6, and every 8 
weeks thereafter *
80 mg. given 
sub cut on week 
0, 40 mg. given 
week one,  then 
every other 
week * 
For under 100 
kg. body weight: 
45 mg. sub cut 
week 0 week 4 
then q 3 months.  
(over 90 kg body 
weight- 90 mg.) 
Type of 
Rx course 
Pulse of 12 
weeks 
Continuous Continuous Continuous Continuous 
Pre-Rx 
w/u 
Baseline 
PPD 
Baseline PPD 
US: Viral 
Hepatitis  
screen Monitor 
Deep Fungal 
where 
geographicallya
ppropriate † 
Baseline PPD 
US: Viral 
Hepatitis  
screen Monitor 
Deep Fungal 
where 
geographicallya
ppropriate † 
Baseline PPD 
US: Viral 
Hepatitis  
screen Monitor 
Deep Fungal 
where 
geographicallya
ppropriate † 
Baseline PPD 
US: Viral 
Hepatitis  
screen Monitor 
Deep Fungal 
where 
geographicallya
ppropriate 
Efficacy 
28% 
achieved a 
PASI 75 at 
12 weeks. 
After 2 
courses the 
PASI-75 
goes to 
40% 
49% achieved 
PASI 75% after 
12 weeks (50 mg 
biw) vs. 59% at 
24 weeks. 
For 3 mg/kg 
body weight: 
PASI 75 was 
72% at 10 
weeks, and 88% 
for 5 mg/kg 
body wegight 
At week 12, 53% 
achieved PASI 
75 or > 
PASI 75 ay week 
12 was 66.7% for 
those taking the 
45 mg dose; 
75.7% who 
received one 90 
mg dose. 
Concurrent 
use of live 
vaccines 
Not 
studied 
Not 
recommended 
Not 
recommended 
Not 
recommended 
Not 
recommended 
Efficacious 
for 
treationg 
PsA 
- + + + -/+ 
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Safety Lympho-
penia, 
malignancy,
serious 
infections 
(Contraind
icated on 
HIV + ) 
Serious 
infections, 
exacerbation of 
demyelinating 
diseases like 
(MS & optic 
neuritis), 
pancytopenia 
malignancy, 
worsening of 
CHF, lupus like 
symptoms, 
+ANA, 
Improves 
glucose 
tolerance 
for diabetics 
lowering  
insulin  
needs 
Infusion-related 
reactions, 
Serious 
infections, 
exacerbation of 
demyelinating 
diseases like 
(MS & optic 
neuritis), 
malignancy, or 
lymphoprilifera-
tive disorders, 
worsening of 
CHF, lupus like 
symptoms, 
+ANA 
Injection site 
reactions, 
exacerbation of 
demyelinating 
diseases like 
(MS & optic 
neuritis), 
cytopenias, 
malignancy, 
worsening of 
CHF, lupus like 
symptoms, 
+ANA  
Clinical 
experience is 
short to compare 
with other 
biologics-  
serious 
infections, 
malignmancy, 
Reversible             
posrerior 
leukoencepha-
lopathy 
syndrome, and 
cardiovascular 
events 
Monitoring CD4+ T-
cell counts 
every 2 
weeks,  
Annual PPD 
 
Annual PPD 
 
Annual PPD 
 
Annual PPD 
 
Long 
Term 
Data 
Data on 
small 
number of 
patients 
PASI response 
continues to 
improve to 
week 24. 
Restarting 
therapy after 
prolonged 
absence restores 
previous 
response.  
Long term 
safety  
profile 
established 
Gradual loss of 
response is 
observed over 
time, especially 
in patients using 
the lower range 
Loss of response 
was observed in 
33 weeks if 
treatment was 
discontinued. 
Recent data 
shows efficacy 
with 
retreatment can 
restore initial 
gains  
Not enough 
time has elapsed 
since its 
introduction for 
long term data 
Pregnancy 
Category 
B B B B B 
* Low dose methotrexate (5-15 mg/week) often used to prevent antibody formation. 
† Persons inhabiting or traveling through Ohio River Valley should be monitored for Histoplasmosis. 
Thoe inhabiting or traveling through San Joaquin Valley should be monitored for Coccidiodomycosis.  
Table 7. Currently available Biologics to treat Psoriasis & Psoriatic Arthritis   
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9.1 Mortality in psoriasis 
Mortality when it comes to psoriasis tends to occur in 3 major settings. The first tends to 
occur as a result of the specific co-morbidities commonly associated with severe psoriasis. 
Abuakara et al looked at a population-based cohort in the UK and found cardiovascular 
death as the major cause of mortality among patients with severe psoriasis. 355 Roth et al 
looked retrospectively over a 20 year period from 1965 to 1985 in France. Though the total 
number of patients documented to die from lethal psoriasis over a century reported in this 
review was 72, this number may be suspect since other causes may have lead to fatality. 
This study found patients whose cause of death was also related to co-morbidities including 
the metabolic syndrome, and visceral amyloidosis. Another group was identified with the 
most severe forms of psoriasis such as erythrodermic psoriasis, pustular psoriasis and 
psoriasis with polyarthritis. The third group was identified in which the cause of death was 
medication given to treat psoriasis. The largest number in this category was patients taking 
methotrexate. 356 Methotrexate should be used cautiously. Evidence is mounting that severe 
psoriasis along with the co-morbidities seen in this disease category may represent a risk factor 
for mortality. Well-controlled long term studies are needed to address this vital aspect. 
9.2 Final comments   
Certain intriguing aspects of psoriasis continue to haunt us as Nickoloff has stated on so 
many occasions. Psoriatic lesions in human skin have distinct clinical, histological and 
immunopathological features, of which not all can be reproduced in other experimental 
models such as mouse skin. Psoriatic skin can be restored grossly to clinical normal 
appearance, in spite of the fact that there may still be histological vestiges of disease activity 
found in clinically normal appearing skin. 357 In spite of the persistence, and often quite 
prominent inflammatory milieu, only rarely does one need to treat infection in psoriatic 
skin. Cellulitis, impetigo, viral or fungal and other parasitic infections are more commonly 
sequelae of atopic dermatitis, and are not generally seen in patients suffering with chronic 
psoriasis. Innate immunity as well as adaptive immunity are likely to play the role in 
maintaining the contrasting difference between these two disorders. 358  It is even rarer to 
record a progression to malignancy in specifically involved psoriatic skin. The interactions 
between the TH1 and TH17 networks needs further elucidation vis a vis the role IL-23 and IL-
22 may play in this relation and its implication in the pathogenesis of psoriasis. As IL-23 has 
been found to promote tumor incidence and growth, this paradox needs to be resolved. A 
search for that elusive antigen which may be responsible to initiate and maintain the cascade 
of events that activates the cytokine network and leads to psoriasis continues. As more is 
learned about the intricacies of this pathogenesis process, it may become clear, that the 
sensitivity of the intercellular and intracellular interactions observed in this complicated 
web of events may be the result of overactive cellular forces, which may not require a 
specific antigenic trigger. Newer therapies are entering the arena.  
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